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The lymphokine interferon gamma (IFN-y), is produced by
mitogen or antigen-stimulated T-lymphocytes (Nathan et al.,
1981). Compared to IFNa and several differences in
biological activity have been reported, particularly in relation
to its immunomodulating and antiproliferative properties.
Evidence from in vitro and in vivo studies suggests that IFN-
y may have a much greater antitumour effect than either
IFNa or # (De Clercq et al., 1982). However it should be
noted that these experiments were performed with IFNs that
were only partially purified and possibly contained
contaminating cytokines that could have contributed to the
biological effects. IFN-y has been reported to exert a direct
cytotoxic effect on certain tumour cell lines (Tyring et al.,
1982). In addition, a number of immunological functions
influenced by IFN-y may synergize with this direct cytotoxic
action. It has been demonstrated that IFN-y can enhance
monocyte cytotoxicity (Kleinerman et al., 1985), macrophage
activity (Nathan et al., 1983) and natural killer (NK) cell
activity (Weigent et al., 1983). Furthermore, IFN-y can
enhance the expression of surface antigens on tumour cells
(Pfizenmaier et al., 1985) and on cells of the immune system,
i.e. macrophages (Wong et al., 1983), which may facilitate
tumour cell cytolysis. Despite the well-recognized anti-
proliferative effects of IFN-y in vitro, the mechanism(s) of its
action are still poorly understood.
Recent advances in molecular biology and recombinant
DNA-technology have resulted in the production of highly
purified rat IFN-y (rRIFN-y). The present study was
undertaken to evaluate the antitumour activity of this new
preparation in vitro and in vivo, using a rat colon adeno-
carcinoma (CC531), previously found to be susceptible to
treatment with immune response modifiers (Marquet et al.,
1984; Eggermont et al., 1986).
Male rats of inbred WAG strain were used. The animals
were bred under specific pathogen-free conditions, weighed
-200g and were 10-12 weeks old. Tumour CC531 is a
chemically-induced, moderately differentiated colon adeno-
carcinoma. It is weakly immunogenic and transplantable in
syngeneic WAG rats (Marquet et al., 1984). In the
experiments reported here the tumour was in its 19th
passage. CC531 is also maintained in tissue culture as a
stationary cell line in RPMI-1640 medium (Gibco, UK),
supplemented with 10% foetal calf serum (FCS). Tumour
cell suspensions were prepared from culture monolayers by
trypsinization for 2min and resuspension in fresh medium.
Details of the cloning, expression and purification of
rRIFN-y have been reported recently (van der Meide et al.,
1986). The preparation used in the current experiments
contained 4x 106 unitsmg-1 protein and had a purity of
98%. The antiviral units were estimated by determining the
protective effect of rRIFN-y against vesicular stomatitis virus
infection of rat fibroblasts in a microtiter assay.
To assess whether rRIFN-y had a direct antiproliferative
effect on CC531, 105 cultured cells were pipetted into 35mm
culture plates (Costar), in a volume of 4ml. One ml of
RPMI-1640 containing 2000, 4000 or 8000 units of rRIFN-y
was added and the plates were incubated at 37°C. In the
controls only RPMI-1640 was added. After 3 days the
number of cells per plate was counted in a microcell counter
and the percentage of living cells determined by using trypan
blue. Each dose of rRIFN-y was tested in triplicate. As
shown in Table I tumour CC531 was not susceptible to
treatment with rRIFN-y in vitro. None of the concentrations
used resulted in inhibition of cell proliferation. There was
also no difference in the percentage of dead cells between
controls and experimental groups.
The first in vivo model used was the subrenal capsule assay
(SRCA). Rats (5 animals per group), were anaesthetized with
ether and following laparotomy both kidneys were exposed.
Tumour cubes (6-8mg) were implanted under the renal
capsule, the animals were sacrificed one week later and
tumour growth assessed by weighing of the enucleated
tumour lumps (Eggermont et al., 1986). The rats were
treated with a daily i.v. dose of 5 x 105 units rRIFN-y, which
was given in a volume of 0.5ml for 5 days, starting on the
day of implantation. Controls were given 0.5ml PBS. The
results of a representative experiment are given in Table II.
Table I Effect of rRIFN-y on growth of tumour CC531 in vitro
Mean number of
rRIFN-y cells (±s.d.) Dead cells (% +s.d.)
None 15.0+3.2 x 105 9.6+0.6
2000 units 14.6+3.5 x 105 13.0+3.4
4000 units 14.4+3.2 x 105 12.6+4.6
8000 units 14.8+2.4 x 105 8.0+3.6
105 tumour cells were cultured in the presence of 2000, 4000 or
8000 units of rRIFN-y for a period of 3 days after which the
number of cells was counted and the percentage of dead cells
determined by trypan blue. Each dose experiment was performed in
triplicate.
Table II Effect of treatment with rRIFN-y on growth of
tumour CC531 in the subrenal capsule assay
Treatment Tumour weight (mg±s.d.)
Controls (PBS) 30.6+7.2
rRIFN-y 18.5+6.5
Tumour CC531 was implanted under the renal capsule, 7
days later the tumours were removed and growth was
assessed by weighing. rRIFN-y therapy at a dose of
5 x 105 unitskg-I day 1 was given i.v. for 5 consecutive days,
starting on the day of implantation. Controls received 0.5ml
PBS. Each group contained 5 animals from which both
kidneys were used.
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It was found that treatment with rRIFN-y led to a
significant inhibition of tumour growth (P<0.05). The mean
tumour weight in the control group was 30.6+7.2mg and
amounted to 18.4+6.5mg in the experimental group.
The second in vivo model in which rRIFN-y was tested
was a liver metastases model. Artificial liver metastases were
evoked by injection of 5 x 105 tumour cells from tissue
culture into the portal vein of WAG rats as described earlier
(Eggermont et al., 1986). The animals were laparotomized 30
days after tumour cell injection and the number of tumour
nodules visible at the surface of the liver lobes was counted.
Each experimental group contained 6-7 animals. Treatment
with rRIFN-y was similar as used in the SRCA. The results
of two different experiments are given in Table III. A highly
significant (P<0.01) inhibition of tumour development as a
result of treatment with rRIFN-y was seen in both
experiments. In experiment I, five animals from the control
group with more than 60 liver nodules were sacrificed on the
day of inspection. The remaining two animals with 24
metastases each and all animals from the rRIFN-y treated
group were kept alive. The controls survived for 52 and 55
days, the treated rats for 88, 91, 95, 95, > 100 and > 100
days, respectively.
Table III Effect of treatment of experimental liver
metastases with rRIFN-y
Treatment Number ofliver metastases
Experiment I
Controls 24,24, >60, >60, >60, >60, >60, >60.
rRIFN-y 0,0,0,1,3,7.
Experiment H
Controls 4,9,20,20, >60.
rRIFN-y 0,0,0,1,2,10.
Liver metastases were evoked by injection of 5.105 CC531
tumour cells into the portal vein. rRIFN-y therapy at a dose
of 5x 105unitskg-1 day-1 was given i.v. for 5 consecutive
days, starting on the day of cell injection. Controls were
given. 0.5ml PBS. The number of metastases was counted
after 30 days.
In a previous communication we reported on the failure to
treat artificial liver metastases from tumour CC531 with
virus-induced, partially purified RIFN-y/fl (Marquet et al.,
1984). The results of the present communication indicate
that rRIFN-y has impressive antitumour activity for the
same tumour in two in vivo models viz. the SRCA and the
liver metastases model. The finding that rRIFN-y had no
effect in vitro, at least not during the culture period of 3 days
employed in the current study, suggests that the in vivo effect
was indirect; possibly mediated by an activated immune
system combined with an enhanced susceptibility of the
tumour (Ball et al., 1986; Feinman et al., 1986). This
putative involvement of the immune system may be an
explanation for the discrepancy between the effect of rRIFN-
v observed in the SRCA and the liver metastases model.
Biological response modifiers are known to be mainly
effective when the tumour load is small; a requirement which
was better fulfilled in the liver model, where single cells were
used, than in the SRCA. An additional explanation for the
surprisingly high efficacy of rRIFN-y against liver metastases
hinges on an important antitumour role of Kupffer cells.
Recent findings by Pearson et al. (1986), also obtained in a
rat liver metastases model, suggest that the activity of
Kupffer cells may have a considerable influence on
metastatic growth in the liver. Stimulation of Kupffer cells
led to a reduction of metastases whereas depression of their
function was associated with a significant increase. We have
found recently that a single injection of rRIFN-y within 24h
leads to increased expression of class II major histo-
compatibility antigens on Kupffer-like cells in the liver
(unpublished results). This activation may be associated with
increased phagocytosis, as has been reported by others
(Nathan et al., 1983) and may have contributed to the low
number of liver metastases and the improved survival found
in the current experiments.
In conclusion, the present study has demonstrated that
rRIFN-y has a marked effect on tumour CC531, especially
in the artificial liver metastases model where a low tumour
load was involved. The finding that rRIFN-y, in the dose
and timing used, had no effect in vitro, suggest that the
activity in vivo was indirect and possibly mediated by an
activated immune system.
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